Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients With Advanced Cancer.

Next Previous
Trial Profile

An Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients With Advanced Cancer.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CEP 11981 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Cephalon; Teva Branded Pharmaceutical Products R&D

Most Recent Events

  • 24 Aug 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
  • 24 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 31 May 2011 Planned End Date changed from 1 Nov 2010 to 1 May 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top